Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

INTRODUCTION: Parkinson’s disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year....

Descripción completa

Detalles Bibliográficos
Autores principales: Vijiaratnam, Nirosen, Girges, Christine, Auld, Grace, Chau, Marisa, Maclagan, Kate, King, Alexa, Skene, Simon, Chowdhury, Kashfia, Hibbert, Steve, Morris, Huw, Limousin, Patricia, Athauda, Dilan, Carroll, Camille B, Hu, Michele T, Silverdale, Monty, Duncan, Gordon W, Chaudhuri, Ray, Lo, Christine, Del Din, Silvia, Yarnall, Alison J, Rochester, Lynn, Gibson, Rachel, Dickson, John, Hunter, Rachael, Libri, Vincenzo, Foltynie, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166598/
https://www.ncbi.nlm.nih.gov/pubmed/34049922
http://dx.doi.org/10.1136/bmjopen-2020-047993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166598/
https://www.ncbi.nlm.nih.gov/pubmed/34049922
http://dx.doi.org/10.1136/bmjopen-2020-047993

Ejemplares similares